MorphoSys and Celgene Create Strategic Alliance to Advance CD38 Cancer Program MOR202 for Patients with Multiple Myeloma
27 June 2013 - 7:58AM
Business Wire
Development of novel therapeutic antibody
approach being evaluated in clinical trials for patients with
multiple myeloma
MorphoSys will hold a conference call on
Thursday, June 27, at 4:00pm CEST (3:00pm GMT/10:00am EDT)
- Celgene secures worldwide rights to
MOR202, whereby the companies will jointly develop MOR202 globally
and co-promote the product in Europe
- MorphoSys retains a 50/50 profit
sharing in its co-promotion territory and is eligible to receive
tiered double-digit royalties outside of the co-promotion
territory
Morphosys (TG:MOR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Morphosys (TG:MOR)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Morphosys AG (Tradegate (DE)): 0 recent articles
More MorphoSys News Articles